SCHEMBL9328018

SCHEMBL9328018

O=C1CCCC[C@@H]1c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 1/20 0.51
MCL1 Q07820 1/20 0.50
MAPT P10636 1/20 0.49
DDB1 Q16531 1/20 0.47
CRBN Q96SW2 1/20 0.47
TP53 P04637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
TLR4 O00206 1/20 0.44
KDM4E B2RXH2 1/20 0.42
CA1 P00915 1/20 0.42
IGF1R P08069 1/20 0.42
ALOX15 P16050 1/20 0.42
NOS1 P29475 2/20 0.42
NOS2 P35228 2/20 0.42
MT-CO2 P00403 2/20 0.41
ALOX5 P09917 2/20 0.41
CTRB1 P17538 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15874652 1.00 SLC18A3 (0.51) SLC18A3MCL1MAPTDDB1CRBN
SCHEMBL190786 1.00 SLC18A3 (0.51) SLC18A3MCL1MAPTDDB1CRBN
SCHEMBL28417815 0.98 SLC18A3 (0.50) SLC18A3MCL1MAPTDDB1CRBN
SCHEMBL15874614 0.98 SLC18A3 (0.50) SLC18A3MCL1MAPTDDB1CRBN
SCHEMBL30882060 0.98 SLC18A3 (0.50) SLC18A3MCL1MAPTDDB1CRBN
Hydrogen Peroxide SCHEMBL14842506 0.98 MCL1 (0.53) SLC18A3MCL1MAPTDDB1CRBN
SCHEMBL4063122 0.98 SLC18A3 (0.50) SLC18A3MCL1MAPTDDB1CRBN
SCHEMBL15660493 0.98 SLC18A3 (0.50) SLC18A3MCL1MAPTDDB1CRBN
Formaldehyde SCHEMBL28906285 0.96 SLC18A3 (0.49) SLC18A3MCL1MAPTDDB1CRBN
SCHEMBL361599 0.94 DDB1 (0.48) SLC18A3MCL1MAPTDDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023154450-A2 (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2023-08-17 WO disclosed
WO-2022261263-A1 METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2022-12-15 WO disclosed
WO-2021134086-A1 ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2021-07-01 WO disclosed
EP-2957575-B1 OPTICALLY ACTIVE POLY(DIPHENYLACETYLENE) COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF AS OPTICAL ISOMER SEPARATING AGENT NAT UNIV CORP KANAZAWA UNIV (JP) 2017-10-18 EP disclosed
EP-2594550-B1 METHOD FOR OXIDIZING ALCOHOLS UNIV TOHOKU (JP) 2016-10-12 EP disclosed
US-8871981-B2 Method for oxidizing alcohols TOHOKU UNIVERSITY (JP) 2014-10-28 US disclosed
US-8871981-B2 Method for oxidizing alcohols TOHOKU UNIVERSITY (JP) 2014-10-28 US disclosed
US-20130172543-A1 METHOD FOR OXIDIZING ALCOHOLS TOHOKU UNIVERSITY (JP) 2013-07-04 US disclosed
US-20130172543-A1 METHOD FOR OXIDIZING ALCOHOLS TOHOKU UNIVERSITY (JP) 2013-07-04 US disclosed
EP-2594550-A1 METHOD FOR OXIDIZING ALCOHOLS Tohoku University (JP) 2013-05-22 EP disclosed
US-5334741-A Contacting surface of substrate with phosphoramidate solution, heating to thermolyse and generate metaphosphate which phosphorylates substrate RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1994-08-02 US disclosed
WO-1994002226-A1 PHOSPHORYLATION WITH MONOMERIC METAPHOSPHATES RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1994-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172543-A1 METHOD FOR OXIDIZING ALCOHOLS ADH1A, ADH1C, ADH5 SLC18A3 2912/4885MCL1 3151/4885MAPT 2182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.